Research programme: anticancer therapeutics - H Lee Moffitt Cancer Center/Feng Biosciences
Latest Information Update: 28 Mar 2024
At a glance
- Originator H. Lee Moffitt Cancer Center and Research Institute; Oncologie
- Developer Feng Biosciences
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer; Gastrointestinal cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in Gastric-cancer in USA
- 28 Mar 2024 No recent reports of development identified for research development in Gastrointestinal-cancer in USA
- 18 Sep 2020 Oncologie is now called OncXerna Therapeutics